Jounce Therapeutics, Inc. Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Jounce Therapeutics, Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy. Its work centers on developing therapies that empower the immune system to attack tumors, with a biomarker-driven approach intended to yield durable benefits for patients. The company is advancing multiple development programs, including JTX-8064, a receptor antagonist targeting LILRB2 (ILT4) to reprogram tumor-associated macrophages, and vopratelimab, which activates ICOS and is studied in ongoing Phase 2 trials. JTX-4014, a PD-1 inhibitor, is pursued for combination use in conjunction with INNATE and SELECT trials, while JTX-1811 (licensed to Gilead) targets CCR8 to deplete regulatory T cells in the tumor microenvironment. Based in the Cambridge area of Massachusetts, Jounce operates within the biotechnology research sector and maintains a focused pipeline designed to enable immune-mediated anti-tumor activity through translational science and predictive biomarkers.

Get verified Jounce Therapeutics, Inc. emails free

Company overview Employee directory